MedTrace Logo

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

NCT00807495 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.

Conditions

  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt's Lymphoma
  • T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
  • Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

Interventions

DRUG

Alisertib

Alisertib capsules

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Millennium Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-10
Primary Completion
2011-01-04
Completion
2013-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807495 on ClinicalTrials.gov